MHRAsafety guidance83% confidence
Opportunities for patients and the public to be involved in the work of the MHRA
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (melanoma) as Novartis.
Regulatory Analysis
How we engage and involve patients and the public in our regulatory decision-making.
Supporting Context
- Therapeutic area
- Oncology · BRAF/MEK Inhibitors
- Sub-indication
- Melanoma
Related signal: Dabrafenib and Trametinib Rollover Study for Continued Patient Access